Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation - PubMed (original) (raw)
Review
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation
Ana Duarte et al. Health Technol Assess. 2017 Nov.
Abstract
Background: Psoriasis is a chronic inflammatory disease that predominantly affects the skin. Adalimumab (HUMIRA®, AbbVie, Maidenhead, UK), etanercept (Enbrel®, Pfizer, New York, NY, USA) and ustekinumab (STELARA®, Janssen Biotech, Inc., Titusville, NJ, USA) are the three biological treatments currently licensed for psoriasis in children.
Objective: To determine the clinical effectiveness and cost-effectiveness of adalimumab, etanercept and ustekinumab within their respective licensed indications for the treatment of plaque psoriasis in children and young people.
Data sources: Searches of the literature and regulatory sources, contact with European psoriasis registries, company submissions and clinical study reports from manufacturers, and previous National Institute for Health and Care Excellence (NICE) technology appraisal documentation.
Review methods: Included studies were summarised and subjected to detailed critical appraisal. A network meta-analysis incorporating adult data was developed to connect the effectiveness data in children and young people and populate a de novo decision-analytic model. The model estimated the cost-effectiveness of adalimumab, etanercept and ustekinumab compared with each other and with either methotrexate or best supportive care (BSC), depending on the position of the intervention in the management pathway.
Results: Of the 2386 non-duplicate records identified, nine studies (one randomised controlled trial for each drug plus six observational studies) were included in the review of clinical effectiveness and safety. Etanercept and ustekinumab resulted in significantly greater improvements in psoriasis symptoms than placebo at 12 weeks' follow-up. The magnitude and persistence of the effects beyond 12 weeks is less certain. Adalimumab resulted in significantly greater improvements in psoriasis symptoms than methotrexate for some but not all measures at 16 weeks. Quality-of-life benefits were inconsistent across different measures. There was limited evidence of excess short-term adverse events; however, the possibility of rare events cannot be excluded. The majority of the incremental cost-effectiveness ratios for the use of biologics in children and young people exceeded NICE's usual threshold for cost-effectiveness and were reduced significantly only when combined assumptions that align with those made in the management of psoriasis in adults were adopted.
Limitations: The clinical evidence base for short- and long-term outcomes was limited in terms of total participant numbers, length of follow-up and the absence of young children.
Conclusions: The paucity of clinical and economic evidence to inform the cost-effectiveness of biological treatments in children and young people imposed a number of strong assumptions and uncertainties. Health-related quality-of-life (HRQoL) gains associated with treatment and the number of hospitalisations in children and young people are areas of considerable uncertainty. The findings suggest that biological treatments may not be cost-effective for the management of psoriasis in children and young people at a willingness-to-pay threshold of £30,000 per quality-adjusted life-year, unless a number of strong assumptions about HRQoL and the costs of BSC are combined. Registry data on biological treatments would help determine safety, patterns of treatment switching, impact on comorbidities and long-term withdrawal rates. Further research is also needed into the resource use and costs associated with BSC. Adequately powered randomised controlled trials (including comparisons against placebo) could substantially reduce the uncertainty surrounding the effectiveness of biological treatments in biologic-experienced populations of children and young people, particularly in younger children. Such trials should establish the impact of biological therapies on HRQoL in this population, ideally by collecting direct estimates of EuroQol-5 Dimensions for Youth (EQ-5D-Y) utilities.
Study registration: This study is registered as PROSPERO CRD42016039494.
Funding: The National Institute for Health Research Health Technology Assessment programme.
Similar articles
- Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ramaekers BLT, Wolff RF, Pouwels X, Oosterhoff M, Van Giessen A, Worthy G, Noake C, Armstrong N, Kleijnen J, Joore MA. Ramaekers BLT, et al. Pharmacoeconomics. 2018 Aug;36(8):917-927. doi: 10.1007/s40273-018-0629-2. Pharmacoeconomics. 2018. PMID: 29480455 Free PMC article. Review. - The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J, Cooper K, Harris P, Picot J, Rose M. Shepherd J, et al. Health Technol Assess. 2016 Apr;20(34):1-222. doi: 10.3310/hta20340. Health Technol Assess. 2016. PMID: 27135404 Free PMC article. Review. - Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Garcia-Doval I, Doney L, Dressler C, Hua C, Hughes C, Naldi L, Afach S, Le Cleach L. Sbidian E, et al. Cochrane Database Syst Rev. 2022 May 23;5(5):CD011535. doi: 10.1002/14651858.CD011535.pub5. Cochrane Database Syst Rev. 2022. PMID: 35603936 Free PMC article. Updated. Review. - Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
Wade R, Grosso A, South E, Rothery C, Saramago P, Schmitt L, Wright K, Palmer S. Wade R, et al. Pharmacoeconomics. 2019 Feb;37(2):131-139. doi: 10.1007/s40273-018-0698-2. Pharmacoeconomics. 2019. PMID: 30112635 Review. - Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N. Rodgers M, et al. Health Technol Assess. 2011 Feb;15(10):i-xxi, 1-329. doi: 10.3310/hta15100. Health Technol Assess. 2011. PMID: 21333232 Free PMC article. Review.
Cited by
- Increasing transparency in indirect treatment comparisons: is selecting effect modifiers the missing part of the puzzle? A review of methodological approaches and critical considerations.
Freitag A, Gurskyte L, Sarri G. Freitag A, et al. J Comp Eff Res. 2023 Oct;12(10):e230046. doi: 10.57264/cer-2023-0046. Epub 2023 Aug 21. J Comp Eff Res. 2023. PMID: 37602779 Free PMC article. Review. - The influence of adalimumab treatment on the systemic gene expression in patients with psoriatic arthritis - preliminary report.
Krawczyk A, Strzałka-Mrozik B, Wcisło-Dziadecka D, Kimsa-Dudek M, Kruszniewska-Rajs C, Gola J. Krawczyk A, et al. Arch Med Sci. 2021 Mar 26;19(4):1080-1091. doi: 10.5114/aoms/113027. eCollection 2023. Arch Med Sci. 2021. PMID: 37560743 Free PMC article. - The MAP2K2 Gene as Potential Diagnostic Marker in Monitoring Adalimumab Therapy of Psoriatic Arthritis.
Krawczyk A, Strzałka-Mrozik B, Juszczyk K, Kimsa-Dudek M, Wcisło-Dziadecka D, Gola J. Krawczyk A, et al. Curr Pharm Biotechnol. 2023;24(2):330-340. doi: 10.2174/1389201023666220628111644. Curr Pharm Biotechnol. 2023. PMID: 35762548 - Ustekinumab therapy changes the transcriptional activity pattern of TGF-β1-3 genes.
Grabarek B, Wcisło-Dziadecka D, Strzałka-Mrozik B, Gola J, Plewka A. Grabarek B, et al. Postepy Dermatol Alergol. 2021 Apr;38(2):244-248. doi: 10.5114/ada.2019.91504. Epub 2020 Jan 9. Postepy Dermatol Alergol. 2021. PMID: 34408592 Free PMC article. - Classifying information-sharing methods.
Nikolaidis GF, Woods B, Palmer S, Soares MO. Nikolaidis GF, et al. BMC Med Res Methodol. 2021 May 22;21(1):107. doi: 10.1186/s12874-021-01292-z. BMC Med Res Methodol. 2021. PMID: 34022810 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical